With the in-depth exploration of the relationship between the immune system and cancer, immunotherapy targeting programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) has revolutionized tumor treatment [4]. This evidence concerns the gene PDCD1 and neoplasm.